Abstract
Pregnant individuals are at heightened risk for severe outcomes from many infectious diseases, including COVID-19. However, they were not included in the initial COVID-19 vaccine clinical trials and current rates of vaccine uptake among pregnant people remain below 15%. We defined the serological and cellular responses to COVID-19 mRNA booster vaccines (i.e., ancestral and BA.5) in pregnant and age-matched non-pregnant females to identify how pregnancy affects immunity against vaccine viruses in addition to novel variants. Blood was collected from participants prior to and 3-5 weeks post booster vaccine. Post-vaccination antibodies from pregnant participants were less cross-reactive to non-vaccine antigens, including XBB1.5 and JN.1, than antibodies from non-pregnant females. Antibodies from non-pregnant females showed strong correlations between IgG1 and FcR binding and greater IgG1:IgG3 ratios and live virus neutralization against all variants. In contrast, antibodies from pregnant participants had lower IgG1:IgG3 ratios and neutralization and greater antibody-dependent NK cell cytokine production and neutrophil phagocytosis, particularly against variants. CD4+ T cells from pregnant patients exhibited reduced polyfunctionality, with IFNγ+ monofunctional dominance. In contrast, among non-pregnant participants, CD4+ T cells displayed greater polyfunctionality, with more IL-21+ cells. Pregnancy may reduce the breadth, composition, and magnitude of humoral and cellular immunity, particularly in response to novel variants, highlighting the need for continued vaccination in this at-risk population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
FDA CERSI U01FD005942, NIH NIAID 75N93021C00045, NIH NCI U54 CA260492
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Johns Hopkins Medicine gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All anonymized data that support the findings of this study and source data for the figures will be available through the NIH/NCI Serological Sciences Network for COVID-19 (SeroNet) data repository, accessible via ImmPort (https://www.immport.org). All other data are available from the corresponding author upon reasonable request.
